Home » Topics » Infection » HIV/AIDS

HIV/AIDS
RSS

Bayer discloses HIV protease inhibitors

Aug. 16, 1996

VX-478 covered under U.S. patent for HIV/AIDS

Aug. 9, 1996

RD4-2025: Selective HIV-1 reverse transcriptase inhibitor in vitro

Aug. 9, 1996

GalaGen's Sporidin G enters phase II/III

Aug. 9, 1996

Immtech's r(m)CRP HIV treatment covered under U.S. patent

Aug. 9, 1996

Cel-Sci now holds full rights to HGP-30

Aug. 9, 1996

BioChem Pharma to challenge Epivir patent

Aug. 9, 1996

A-76202: Alpha-glucosidase/sucrase-isomaltase complex inhibitor from Sankyo

Aug. 9, 1996

Emory University files Epivir patent infringement action

Aug. 9, 1996

Study of Epivir's effect on HIV survival and disease progression terminated

Aug. 9, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 16, 2026.
SERPINB1 as potential biomarker for spinocerebellar ataxia type 2
BioWorld Science
Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
JPM 2026: Year kicks off with biopharma Q4 revenue and guidance
BioWorld
It was a battle of the companies with drugs for transthyretin-mediated amyloidosis on the first day of the J.P. Morgan 2026 Healthcare Conference with Alnylam...